Galle P et al. Ramucirumab for patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein following sorafenib: Outcomes by liver disease aetiology front wo randomised, placebo-controlled phase 3 studies (REACH-2 and REACH). (Abstract GS-09)
Letermovir non-inferieur aan valganciclovir voor CMV-profylaxe na niertransplantatie
nov 2023 | Niertransplantatie, Virale infecties